• Inhibiting osteoclastogenesis and osteolysis-mediated inflammation in vivo• Inhibiting the migration, invasion, and colony formation of MDA-MB-231 breast cancer cells in vitro• Inhibiting both MDA-MB-231 activated and RANKL-induced osteoclast formation from BM-derived mononuclear cells in vitro• Suppressing the expression of osteolysis-related factors in MDA-MB-231 cells• Inhibiting NF-κB pathway activation in BM-derived mononuclear cells• Decreasing the osteolysis in vivo. This evidence concerns the gene NFKB1 and breast carcinoma.